Inozyme Pharma Raises USD 67 Million in Series A2 Financing
Inozyme Pharma- a Boston-based biotechnology company, solely focused on developing novel therapies to treat rare diseases, has raised USD 67 million. The company plans to use this funding to progress its lead asset INZ-701, into clinical trials. INZ-701 is an enzyme which will be used to compensate for the lack of plasma pyrophosphate, which is known to cause a rare mineralisation disorder of the circulatory system, bones, and kidneys.
Shanghai Miracogen partners with Synaffix to accelerate its pipeline
Shanghai Miracogen-a leading China-based antibody-drug conjugate (ADC) developer, has partnered...
